NCT05214794View on ClinicalTrials.gov

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

June 4, 2024

Study Completion Date

July 30, 2024

Conditions

Systemic Sclerosis

Interventions

DRUG

nemolizumab

nemolizumab will be administered subcutaneous injection

Trial Locations (1)

Unknown

The University of Tokyo Hospital, Tokyo

All Listed Sponsors

lead

Maruho Co., Ltd.

INDUSTRY